Yes, Elite Pharmaceuticals, Inc. (ELTP) has hired an M&A advisory firm to support its ongoing exploration of strategic alternatives, including potential mergers, acquisitions, or a sale of the business. This engagement was initiated in late 2024, with the firm formally selected by February 2025. Key details from public disclosures include:
• Current Engagement (2024–Ongoing): The company is actively working with an unnamed M&A advisory partner (referred to as “our M&A company” in earnings discussions) to evaluate acquisition targets, develop marketing materials, identify buyers, and facilitate negotiations. In Q1 FY2026 (ended June 30, 2025), Elite incurred $600,000 in consulting costs specifically tied to M&A activities and option evaluations. The process has a flexible timeline extending through the end of 2025, with a focus on securing an acceptable offer to maximize shareholder value. If no suitable deal materializes, the company plans to pursue a Nasdaq uplisting by Q1 2026 while continuing M&A efforts. No further details on the firm’s identity (e.g., investment bank or boutique advisor) were disclosed in earnings calls, SEC filings, or news sources.
• Historical Engagement (2006): Elite entered into a Financial Advisory Agreement with Indigo Ventures LLC on July 1, 2006, to provide advisory services potentially related to strategic transactions, including M&A. This was disclosed in SEC filings but appears unrelated to current activities.
Despite extensive searches across news, SEC documents, earnings transcripts, financial forums, and contracts databases, no additional names or specifics for the current advisor emerged. If this refers to a different time period or context, more details could help refine the search.
Market Data 
Markets 
AI
